April 11, 2026 - 02:08

Membrane Technology & Research (MTR) has successfully closed a significant $27 million equity financing round. The capital infusion is earmarked to accelerate the worldwide deployment of the company's proprietary membrane systems, which are critical for both industrial separations and the pressing global challenge of carbon capture.
The funding will directly support the scaling of MTR's operations and technology to meet rising demand. The company's membrane technology is designed to selectively separate gases, offering an energy-efficient method to capture carbon dioxide emissions from industrial sources before they enter the atmosphere. This positions MTR at the forefront of providing scalable solutions for hard-to-abate sectors seeking to reduce their environmental footprint.
Beyond carbon capture, the firm's separation systems are utilized in various industrial processes, including natural gas purification and hydrogen recovery. The new investment underscores growing confidence in membrane-based separation as a versatile and cost-effective technology for multiple industries. Company leadership stated the funds will enable broader commercialization efforts and enhance their capacity to deliver large-scale, impactful projects globally, contributing to both industrial efficiency and climate goals.
September 30, 2026 - 01:50
Space Force Turns to Laser Systems to Shield Launch Sites from Drone ThreatsThe U.S. Space Force is moving forward with plans to deploy laser technology as part of a broader effort to defend its launch facilities from unauthorized drones. The initiative focuses on...
September 29, 2026 - 04:58
DIU Seeks Investors in Counter-Unmanned Systems TechnologyThe Defense Innovation Unit is looking for private investors to back companies working on counter unmanned systems technology. The effort targets firms building tools to detect, track, and disable...
September 28, 2026 - 02:02
Novo Nordisk (CPSE:NOVO B) Secures Long-Acting Injectable Technology In €1.165 Billion Nanexa Licensing AgreementNovo Nordisk has entered a global licensing agreement with Swedish drug delivery company Nanexa, valued at up to 1.165 billion euros. The deal centers on Nanexa`s PharmaShell technology, a platform...
September 27, 2026 - 08:32
New Biochip Enables Real-Time Tracking of Parkinson's Treatment ResponseResearchers have created a biochip technology that allows for real-time monitoring of how Parkinson`s disease patients respond to treatment. The development comes from a team working on advanced...